Ordenar

Buscar

01/08/2026 CSF and plasma tau biomarkers in the Down syndrome-Alzheimer's disease continuum
Arranz, J, Lantero-Rodriguez, J, Braun-Wohlfahrt, LS, Vaqué-Alcázar, L, Rodriguez-Baz, I, Kac, PR, Arslan, B, Maure-Blesa, L, Pertierra, L, Videla, L, Carmona-Iragui, M, Benejam, B, Soriano, LD, Barroeta, I, Fernández, S, Bejanin, A, Lleó, A, Ashton, NJ, Zetterberg, H, Fortea, J, Alcolea, D, Montoliu-Gaya, L. CSF and plasma tau biomarkers in the Down syndrome-Alzheimer's disease continuum. EBioMedicine. 2026; 130DOI:10.1016/j.ebiom.2026.106370. PMID:42435584. IF:10.800(Q1/1D).
01/08/2026 Clinical and Neuroimaging Effects of Mindfulness-Based Cognitive Therapy for Symptomatic Obsessive-Compulsive Disorder Patients after First-Line Treatments: A Randomised Controlled Trial
Serra-Blasco, M, Miquel-Giner, N, Vicent-Gil, M, Porta-Casteràs, D, Martínez-Zalacaín, I, Cano, M, de la Peña-Arteaga, V, Mar-Barrutia, L, Alemany-Navarro, M, Soriano-Mas, C, Lopez-Solà, M, Andrews-Hanna, JR, Portella, MJ, Soler, J, Cardoner, N, Alonso, P, Lopez-Solà, C. Clinical and Neuroimaging Effects of Mindfulness-Based Cognitive Therapy for Symptomatic Obsessive-Compulsive Disorder Patients after First-Line Treatments: A Randomised Controlled Trial. PSYCHOTHERAPY AND PSYCHOSOMATICS. 2026; 95(4)DOI:10.1159/000548961. PMID:41115123. IF:17.400(Q1/1D).
01/08/2026 Inflammatory myopathies with anti-TIF1y antibodies and their association with neoplasms: a study of a series of 28 cases
Baena, AMG, Mir, MC, Faja, GV, Osorio, LJM, Vilaseca, VG. Inflammatory myopathies with anti-TIF1y antibodies and their association with neoplasms: a study of a series of 28 cases. MEDICINA CLINICA. 2026; 166(8)DOI:10.1016/j.medcli.2026.107496. PMID:. IF:2.100(Q2/3D).
01/08/2026 Bladder Tumor Location Matters: Trigone and Bladder Neck Involvement Predict Worse Oncological Outcomes in High-Grade Non-Muscle-Invasive Bladder Cancer
Slusarczyk, A, Moschini, M, Krajewski, W, Scilipoti, P, Velasco, JC, Mertens, LS, Mori, K, Subiela, JD, Garbas, K, Duran, PD, Claps, F, Contieri, R, Domanski, P, Tully, K, Grobet-Jeandin, E, Puentedura, AL, Lijnen, RAG, Fertitta, G, Longoni, M, Del Giudice, F, Gallioli, A, Laukhtina, E, Marcq, G, Mari, A, Amodeo, A, Afferi, L, Albisinni, S, Boorjian, SA, Soria, F, Briganti, A, Shariat, SF, Gontero, P, Radziszewski, P, Pradere, B. Bladder Tumor Location Matters: Trigone and Bladder Neck Involvement Predict Worse Oncological Outcomes in High-Grade Non-Muscle-Invasive Bladder Cancer. ANNALS OF SURGICAL ONCOLOGY. 2026; 33(8)DOI:10.1245/s10434-026-19476-6. PMID:41862762. IF:3.500(Q1/2D).
01/08/2026 ASO Visual Abstract: First-in-Human Study of CEB-01: Novel Loco-Regional SN-38-Releasing Membrane to Prevent Local Recurrence in Retroperitoneal Sarcomas
Gonzalez, JA, Sebio, A, Martin-Broto, J, Hindi, N, Villarejo-Campos, P, Jiménez, M, Díaz-Beveridge, R, Castellanos, JFO, Andújar, RL, Alvarez, RA, Asencio, JM, Serrano, C, Conde, NR, Boix, SC, Krauel, L, Codina, HC, García, JAT, de Llanos, EL, Ninou, AH, Campos, AP, Gruber, AK, Pousa, AL. ASO Visual Abstract: First-in-Human Study of CEB-01: Novel Loco-Regional SN-38-Releasing Membrane to Prevent Local Recurrence in Retroperitoneal Sarcomas. ANNALS OF SURGICAL ONCOLOGY. 2026; 33(8)DOI:10.1245/s10434-026-19614-0. PMID:41984420. IF:3.500(Q1/2D).
01/08/2026 First-in-Human Study of CEB-01: Novel Loco-Regional SN-38-Releasing Membrane to Prevent Local Recurrence in Retroperitoneal Sarcomas
Gonzalez, JA, Sebio, A, Martin-Broto, J, Hindi, N, Villarejo-Campos, P, Jiménez, M, Díaz-Beveridge, R, Castellanos, JFO, Andújar, RL, Alvarez, RA, Asencio, JM, Serrano, C, Conde, NR, Boix, SC, Krauel, L, Codina, HC, García, JAT, de Llanos, EL, Ninou, AH, Campos, AP, Gruber, AK, Pousa, AL. First-in-Human Study of CEB-01: Novel Loco-Regional SN-38-Releasing Membrane to Prevent Local Recurrence in Retroperitoneal Sarcomas. ANNALS OF SURGICAL ONCOLOGY. 2026; 33(8)DOI:10.1245/s10434-026-19487-3. PMID:41998462. IF:3.500(Q1/2D).
26/07/2026 Association between chemotherapy use and prognosis in young patients with stage I-II ER+/HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching (vol 242 , 116818 , 2026 )
Di Grazia, G, Di Lauro, V, Morchón-Araujo, D, Nucera, S, Figuero-Pérez, L, Calleja-Holgado, FJ, Sánchez, DP, Wallbaum, B, Vargas, PR, Palleschi, M, Musolino, A, Cobos, GZ, Paradis, AL, Barroso, G, Cano, OC, Portulas, ED, Caltavituro, A, Buono, G, Gillaranz, YJ, Echavarria, I, López-Tarruella, S, Sirvén, MB, Martinez-Sáez, O, Adamo, B, Mun, M, Arpino, G, Bayona, RS, De Laurentiis, M, Rodriguez, CA, Pascual, T, Losada, MV, Schettini, F. Association between chemotherapy use and prognosis in young patients with stage I-II ER+/HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching (vol 242 , 116818 , 2026 ). EUROPEAN JOURNAL OF CANCER. 2026; 243DOI:10.1016/j.ejca.2026.116852. PMID:42250453. IF:7.100(Q1/2D).
26/07/2026 Papillary renal cell carcinoma-exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review
Ahrens, M, Haanen, J, Albiges, L, Goupil, MG, Boleti, E, Gravis, G, Fléchon, A, Grimm, MO, Bedke, J, Barthélémy, P, Castellano, D, Mellado, B, Ivanyi, P, Rottey, S, Flörcken, A, Suárez, C, Maroto, JP, Grünwald, V, Oosting, S, Kopecky, J, Zschäbitz, S, Boegemann, M, Buchler, T, Niegisch, G, Goebell, PJ, Waddell, T, Joly, F, Priou, F, Retz, M, Siemer, S, Zimmermann, U, Deckbar, D, Burkholder, I, Hartmann, A, Bergmann, L. Papillary renal cell carcinoma-exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review. EUROPEAN JOURNAL OF CANCER. 2026; 243DOI:10.1016/j.ejca.2026.116816. PMID:42235464. IF:7.100(Q1/2D).
17/07/2026 Modelling Hepatitis B virus related hospital discharges in Spain: ARIMAX based liver disease forecasting tool for hospital workload and mortality progression (Vol 21, e0329751, 2026)
Acosta, L, Soldevila, N, Torner, N, Avellon, A, Hernando, V, Borras, E, Martínez, A, Pericas, C, Rius, C, Godoy, P, Dominguez, A. Modelling Hepatitis B virus related hospital discharges in Spain: ARIMAX based liver disease forecasting tool for hospital workload and mortality progression (Vol 21, e0329751, 2026). PLoS One. 2026; 21(7)DOI:10.1371/journal.pone.0354253. PMID:. IF:2.600(Q2/4D).
16/07/2026 Real-world treatment patterns and outcomes in moderate-to-severe SLE: findings from the Spanish SPOCS cohort
Lozano-Rivas, N, Rúa-Figueroa, I, Freire-González, M, Turrión, A, Castellvi, I, Ajo, JB, Calvo-Alén, J, Ortego-Centeno, N, Díaz-Encarnación, M, Pego-Reigosa, JM, Ding, B, Galvez-Fernandez, M, Bahamontes-Rosa, N, Cervera, R. Real-world treatment patterns and outcomes in moderate-to-severe SLE: findings from the Spanish SPOCS cohort. Lupus Science & Medicine. 2026; 13(2)DOI:10.1136/lupus-2026-002054. PMID:42463277. IF:3.500(Q2/3D).
15/07/2026 International analysis of reimbursement rates and clinical benefit of genitourinary cancer drugs across Canada, France, England, Wales, Scotland, Spain, Italy, and Portugal
Tapia, JC, Gavira, J, Matthews, D, Santoni, M, Young, M, Blondel, L, Flippot, R, Frazer, R, Anguera, G, Maroto, P. International analysis of reimbursement rates and clinical benefit of genitourinary cancer drugs across Canada, France, England, Wales, Scotland, Spain, Italy, and Portugal. INTERNATIONAL JOURNAL OF CANCER. 2026; 159(2)DOI:10.1002/ijc.70379. PMID:41653082. IF:4.700(Q1/3D).
15/07/2026 A controlled-release mitochondrial protonophore attenuates early- and late-stage atheroprogression in mice
dos Santos, BG, Brisnovali, NF, Haney, C, Coven, M, Sebzevari, HL, Gaebel, L, Zhang, XB, Sun, JAT, Canfrán-Duque, A, Rotllan, N, Nasiri, A, Kahn, M, McAlpine, CS, Shulman, GI, Goedeke, L. A controlled-release mitochondrial protonophore attenuates early- and late-stage atheroprogression in mice. Science Translational Medicine. 2026; 18(858)DOI:10.1126/scitranslmed.adv1815. PMID:42455898. IF:14.600(Q1/1D).
14/07/2026 Clinical Impact and Prognostic Value of Alzheimer Disease Biomarkers in the Very Old
Ceriello, C, Torres, OH, Rubio-Guerra, S, García-Castro, J, Selma-Gonzalez, J, Sala, I, Sánchez-Saudinós, MB, Videla, L, Vera-Campuzano, E, Arranz, J, Rodríguez-Baz, I, Maure-Blesa, L, Dols-Icardo, O, Valldeneu, S, Barroeta, I, Santos-Santos, M, Carmona-Iragui, M, Vaqué-Alcázar, L, Alvarez-Sanchez, E, Lorente, O, Carreras, M, Bejanin, A, Belbin, O, Lleó, A, Fortea, J, Alcolea, D, Illán-Gala, I. Clinical Impact and Prognostic Value of Alzheimer Disease Biomarkers in the Very Old. NEUROLOGY. 2026; 107(1)DOI:10.1212/WNL.0000000000218180. PMID:42308436. IF:8.500(Q1/1D).
14/07/2026 Consensus Definitions of Disease Activity and Clinical Outcomes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Allen, JA, Eftimov, F, Querol, L, Sommer, C, Dimachkie, MM, Fix, C, Gable, K, Gorson, KC, Harbo, T, Karam, C, Koike, H, Kuitwaard, K, Lunn, MP, Nobile-Orazio, E, Pasnoor, M, Rajabally, YA, Peric, S, Reisin, R, Butler, L. Consensus Definitions of Disease Activity and Clinical Outcomes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy. NEUROLOGY. 2026; 107(1)DOI:10.1212/WNL.0000000000218159. PMID:42302218. IF:8.500(Q1/1D).
12/07/2026 Development and Inter-Laboratory Validation of Multiplex Flow Cytometry Assay for Autoimmune Nodopathy
Min, YG, Llarch, P, Lleixà, C, Ju, W, Shin, HY, Ban, JJ, Querol, L, Sung, JJ. Development and Inter-Laboratory Validation of Multiplex Flow Cytometry Assay for Autoimmune Nodopathy. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2026; 31(3)DOI:10.1111/jns.70137. PMID:42437960. IF:3.200(Q2/4D).
08/07/2026 Ten-year update on the European Association of Urology Robotic Section (ERUS) fellowship training for robot-assisted radical prostatectomy
Paciotti, M, Wagner, C, Frego, N, Beatrici, E, Mottaran, A, Bravi, CA, Piramide, F, Lores, MP, Sarchi, L, Piro, A, Farinha, R, Sorce, G, Balestrazzi, E, Nocera, L, Ruvolo, CC, Rebuffo, S, Liakos, N, Dell'Oglio, P, Wenzel, M, Moschovas, MC, Turri, F, Di Maida, F, Lambert, E, Wurnschimmel, C, De Groote, R, van Cleynenbreugel, B, Larcher, A, Andras, I, Buffi, NM, van der Poel, HG, Breda, A, Mottrie, A, Gallagher, AG. Ten-year update on the European Association of Urology Robotic Section (ERUS) fellowship training for robot-assisted radical prostatectomy. Bjui Compass. 2026; 7(7)DOI:10.1002/bco2.70227. PMID:42428668. IF:(Q/D).
07/07/2026 Developing a digital assessment tool for childhood eating habits: a validation and reliability study in Mexican schoolchildren
Olguín-Hernández, Z, Hernández-Islas, A, Martínez-Andrade, GO, Fernández-Cortés, TL, Delgadillo-Badillo, E, Rojo-López, MI, Julve, J, Niño-Narvión, J, Calderón-Ramos, ZG, Ramírez-Moreno, E. Developing a digital assessment tool for childhood eating habits: a validation and reliability study in Mexican schoolchildren. Nutrire. 2026; 51(2)DOI:10.1186/s41110-026-00502-2. PMID:. IF:(Q/D).
04/07/2026 Proteomic analysis reveals divergent inflammatory mechanisms of COVID-associated Guillain-Barré syndrome
Ulutekin, C, Can, A, Súkeníková, L, Querol, L, Juntas-Morales, R, Llauradó, A, Dietmann, A, Weiss, T, Latorre, D, Becher, B, Ingelfinger, F, Schreiner, B. Proteomic analysis reveals divergent inflammatory mechanisms of COVID-associated Guillain-Barré syndrome. JOURNAL OF MOLECULAR MEDICINE-JMM. 2026; 104(1)DOI:10.1007/s00109-026-02698-2. PMID:42399536. IF:4.200(Q1/3D).
01/07/2026 Mullerian adenosarcoma of the uterus, ovary and peritoneum: Whole transcriptomic digital spatial profiling (DSP) in a cohort of 42 tumors
D'Angelo, E, Kingsley, LG, Espinosa, I, Cipriani, V, Marotta, A, Nasr, S, Zdravkovic, S, Howitt, BE, Prat, J. Mullerian adenosarcoma of the uterus, ovary and peritoneum: Whole transcriptomic digital spatial profiling (DSP) in a cohort of 42 tumors. HUMAN PATHOLOGY. 2026; 173DOI:10.1016/j.humpath.2026.106117. PMID:41932512. IF:2.600(Q2/4D).
01/07/2026 Patient-and Clinician-reported Outcomes, Safety and Efficacy Profile of Tirbanibulin 1% for Actinic Keratosis Under Conditions Close to Routine Clinical Practice in Spain and Italy (TIRBASKIN Study)
Gilaberte, Y, Yélamos, O, Cañueto, J, Serra-Guillén, C, Conti, A, Pajuelo, F, Lecchi, A, Cappello, V, Kostov, B, Padullés, L, Romanelli, M. Patient-and Clinician-reported Outcomes, Safety and Efficacy Profile of Tirbanibulin 1% for Actinic Keratosis Under Conditions Close to Routine Clinical Practice in Spain and Italy (TIRBASKIN Study). Actas Dermo-Sifiliograficas. 2026; 117(7)DOI:10.1016/j.ad.2026.104632. PMID:41864466. IF:(Q/D).